Background
==========

Endophthalmitis is one of the most vision-threatening ocular complications following intraocular surgeries and open-globe injuries. The incidence of polymicrobial infection in the report of the Endophthalmitis Vitrectomy Study (EVS) Group was 9.3% \[[@B1]\]. The incidence of polymicrobial endophthalmitis after open-globe injuries has been reported from 5.3% to 47.6% \[[@B2]-[@B6]\], while it has been reported to be 0.0% to 17% in various postoperative endophthalmitis series \[[@B6]-[@B12]\]. There are limited published series reporting the etiology and outcome of polymicrobial endophthalmitis \[[@B12]\]. No large series are available in the literature on etiology and visual acuity (VA) outcomes of polymicrobial endophthalmitis cases.

The purpose of the present study is to evaluate the prevalence, causative organisms, and visual acuity outcomes in patients with culture-proven polymicrobial endophthalmitis in a teaching hospital.

Results and discussion
======================

Results
-------

Polymicrobial endophthalmitis was seen in 43 (3.88%) out of 1,107 culture-proven endophthalmitis patients. There were 31 male patients as compared to 12 female patients with polymicrobial infection. Forty-two patients had grown two isolates and one patient had grown three isolates, yielding a total of 87 isolates (Table [1](#T1){ref-type="table"}).

###### 

Clinical profile of patients with polymicrobial endophthalmitis

  **SR number**   **Age**/**gender**   **Setting**                **Visual acuity** (**presenting**)   **Primary intervention**                **Secondary intervention** (**Y**/**N**)   **Visual acuity** (**final**)   **Organisms**
  --------------- -------------------- -------------------------- ------------------------------------ --------------------------------------- ------------------------------------------ ------------------------------- -----------------------------------------------------------
  1               7 years/F            Trauma                     PR inacc                             PPV + IOAB                              N                                          No PL                           *Staphylococcus epidermidis*, *Streptococcus pneumoniae*
  2               5 years/M            Trauma                     PR inacc                             STR + PPV + IOAB                        N                                          CF 2 m                          *Alpha hemolytic Streptococcus*, *Haemophilus influenzae*
  3               60 years/M           Cataract surgery           20/200                               Vit Bx + IOAB                           N                                          20/400                          *Bacillus*, *Corynebacterium*
  4               6 years/F            Trauma                     PR inacc                             STR + PPV + IOAB                        N                                          No PL                           *Alpha hemolytic Streptococcus*, *Acromonas*
  5               8 years/F            Trauma                     PR inacc                             STR + PPV + IOAB                        N                                          No PL                           *Bacillus*, *S*. *pneumoniae*
  6               35 years/F           Trauma                     PR inacc                             IOFB removal + PPV + IOAB               N                                          CF 1/2 m                        *Aspergillus* sp., *Bacillus*
  7               45 years/M           Trauma                     PR inacc                             STR + PPV + IOAB                        N                                          No PL                           *S*. *epidermidis*, *Bacillus*
  8               15 years/M           Trauma                     PR acc                               IOFB removal + PPV + IOAB               N                                          20/60                           *Alpha hemolytic Streptococcus*, *Clostridium*
  9               64 years/M           Penetrating keratoplasty   20/1200                              Vit Bx + IOAB                           N                                          20/160                          *S*. *epidermidis*, *S*. *pneumoniae*
  10              36 years/M           Trabeculectomy             PR inacc                             PPV + IOAB                              N                                          20/40                           *S*. *pneumoniae*, *Fusarium*
  11              73 years/M           Cataract surgery           PR acc                               PPV + IOAB                              N                                          PR inacc                        *S*. *epidermidis*, *Aspergillus*
  12              8 years/M            Trauma                     PR inacc                             IOFB removal + PPV + IOAB               N                                          No PL                           *S*. *epidermidis*, *Alpha hemolytic Streptococcus*
  13              39 years/F           Trauma                     PR inacc                             STR + PPV + IOAB                        N                                          PR inacc                        *Chrysomonads*, *Fusarium*
  14              23 years/M           Trauma                     PR acc                               PPV + IOAB                              N                                          20/400                          *S*. *epidermidis*, *Aspergillus*
  15              4 years/M            Trauma                     PR inacc                             STR + PPV + IOAB                        N                                          PR acc                          *S*. *epidermidis*, *Aspergillus*
  16              16 years/M           Trauma                     PR inacc                             IOFB removal + PPV + IOAB               N                                          PR inacc                        *S*. *epidermidis*, *S*. *pneumoniae*
  17              71 years/M           Trabeculectomy             PR acc                               STR + PPV + IOAB                        N                                          20/50                           *Moraxella*, *S*. *epidermidis*
  18              45 years/M           Cataract surgery           20/25                                Vit Bx + IOAB                           N                                          20/25                           *S*. *epidermidis*, *Aspergillus*
  19              18 years/M           Trauma                     PR acc                               PPV + IOAB                              N                                          20/1200                         *S*. *epidermidis*, *Aspergillus*
  20              38 years/M           Trauma                     PR acc                               PPV + IOAB                              N                                          20/40                           *S*. *epidermidis*, *Clostridium*
  21              60 years/M           Cataract surgery           PR acc                               PPV + IOAB                              N                                          PR inacc                        *Corynebacterium*, *Aspergillus*
  22              38 years/M           Trauma                     PR acc                               STR + PPV + IOAB                        Y                                          PR acc                          *Bacillus*, *Alpha hemolytic Streptococcus*
  23              14 years/M           Endogenous                 Pr acc                               PPL + PPV + IOAB                        N                                          No PL                           *S*. *pneumoniae*, *S*. *aureus*
  24              4 years/F            Trauma                     PR acc                               PPV + IOAB                              N                                          No PL                           *S*. *pneumoniae*, *H*. *influenzae*
  25              50 years/M           Trauma                     PR inacc                             ECCE + PPV + IOAB                       Y                                          No PL                           *S*. *pneumoniae*, *Pseudomonas*
  26              57 years/M           Penetrating keratoplasty   PR acc                               PPV + IOAB                              N                                          CF-1/2m                         *S*. *pneumoniae*, *H*. *influenzae*
  27              7 years/F            Trauma                     PR acc                               STR + PPV + IOAB                        Y                                          No PL                           *S*. *pneumoniae*, *E*. *coli*
  28              7 years/F            Trauma                     PR acc                               PPL + PPV + IOAB                        N                                          No PL                           *S*. *pneumoniae*, *Neisseria*
  29              3 years/M            Trauma                     PR acc                               PPV + IOAB                              N                                          No PL                           *S*. *pneumoniae*, *Pseudomonas*
  30              8 years/M            Trauma                     PR acc                               PPL + PPV + IOAB                        Y                                          No PL                           *S*. *pneumoniae*, *H*. *influenzae*
  31              11 years/M           Trauma                     PR inaac                             CTR + PPL + PPV + IOAB                  N                                          No PL                           *Bacillus*, *Enterococcus*, *Pantoea*
  32              6 years/M            Trauma                     PR acc                               STR + PPL + PPV + IOAB + IOFB Removal   Y                                          PL                              *Enterococcus*, *Stenotrophomonas*
  33              3 years/F            Trauma                     No PL                                STR + PPL + PPV + IOAB                  N                                          No PL                           *Paenibacillus thiaminolyticus*, *Enterobacter*
  34              1 month/M            Endogenous                 PL                                   Vit Bx + IOAB                           N                                          No PL                           *S*. *pneumoniae*, *Pseudomonas*
  35              4 years/M            Trauma                     PR acc                               CTR + PPL + PPV + IOAB                  Y                                          HM+                             *Streptococci*, *Fusarium*
  36              57 years/F           Cataract surgery           20/40                                Vit Bx + IOAB                           Y                                          20/20                           *Pseudomonas*, *Aspergillus*
  37              3 years/M            Trauma                     PL+                                  CTR + PPL + PPV + IOAB                  Y                                          CF-2m                           *S*. *epidermidis*, *Corynebacterium*
  38              14 years/M           Trauma                     PR inacc                             PPL + PPV + IOAB                        Y                                          20/200                          *Streptococcus mitis*, *Fusarium*
  39              5 years/M            Trauma                     PR acc                               PPV + IOAB                              Y                                          PL                              *Streptococci*, *Pseudomonas*
  40              31 years/M           Endogenous                 PR acc                               PPV + IOAB                              Y                                          HM+                             *S*. *epidermidis*, *E*. *coli*
  41              18 years/F           Trauma                     PL                                   PPL + PPV + IOAB + Ampho B              Y                                          20/25                           *Pseudomonas*, *S pneumonia*
  42              19 years/M           Trauma                     HM+                                  CTR + PPL + PPV + IOAB + Ampho B        Y                                          PL                              *Streptococci*, *Pseudomonas*
  43              34 years/F           Trauma                     PL                                   PPV + IOAB                              Y                                          PL                              *Corynebacterium*, *Aspergillus*

*PR* acc, projection of rays accurate; *PR* inacc, projection of rays inaccurate; *HM+*, hand motion close to face present; *PL*, perception of light; *PPL*, pars plana lensectomy; *PPV*, pars plana vitrectomy; *Vit Bx*, vitreous biopsy; *IOAB*, intraocular antibiotics; *IOFB*, intraocular foreign body; *CTR*, corneal tear repair; *STR*, scleral tear repair; *Ampho B*, intravitreal amphotericin B.

Clinical presentation
---------------------

Overall, the presenting visual acuity was light perception in 38 patients and was greater than or equal to hand motion in 5 patients. Thirty-eight patients underwent core vitrectomy, and five patients underwent vitreous biopsy as the first intervention. In all the patients, the organisms were isolated and identified from the first vitreous sample, collected during the first procedure (vitreous biopsy/vitrectomy). Gram-positive organisms were the most common isolates (*n* = 53; 60.9%), followed by Gram-negative organisms (*n* = 22; 25.3%) and fungi (*n* = 12; 13.8%). *Staphylococcus epidermidis* (*n* = 14; 16.1%) and *Streptococcus pneumoniae* (*n* = 13; 14.9%) were the most common organisms. The endophthalmitis categories were open-globe injury (31/43; 72.1%), postoperative endophthalmitis (9/43; 20.9%), and endogenous endophthalmitis (3/43; 6.9%) (Table [2](#T2){ref-type="table"}).

###### 

Comparison of secondary interventions and visual outcome among different etiologies of polymicrobial endophthalmitis

                                               **Trauma**   **Postoperative**   **Endogenous**
  ------------------------------------------- ------------ ------------------- ----------------
  Number of patients                               31               9                 3
  Undergoing secondary intervention            12 (38.7%)       1 (11.1%)         1 (33.3%)
  Unfavorable visual outcome (VA \< 20/200)    27 (87.1%)       4 (44.4%)          3 (100%)

Antibiotic susceptibilities
---------------------------

Gram-positive bacteria were most sensitive to vancomycin (100%) and chloramphenicol (96%). Gram-negative bacteria were most sensitive to ciprofloxacin (86.4%) and ofloxacin (81.2%) (Table [3](#T3){ref-type="table"}).

###### 

Antibiotic susceptibility of isolates in polymicrobial endophthalmitis

  **Antibiotic**     **Sensitivity of gram**-**positive bacteria(%)**   **Sensitivity of gram**-**negative bacteria(%)**
  ----------------- -------------------------------------------------- --------------------------------------------------
  Amikacin                                 57.1                                               61.9
  Cefazolin                                81.1                                               33.3
  Ceftazidime                              61.1                                               63.1
  Ciprofloxacin                            82.7                                               86.4
  Chloramphenicol                           96                                                72.7
  Gentamycin                                74                                                63.6
  Gatifloxacin                             82.6                                                80
  Ofloxacin                                67.7                                               81.2
  Vancomycin                               100                                                45.4
  Moxifloxacin                             88.2                                                70

Secondary intervention
----------------------

Twelve out of 31 patients (38.7%) having endophthalmitis following open-globe injury had secondary intervention as compared to postoperative (1/9; 11.1%) and endogenous (1/3; 33.3%) endophthalmitis. The number of patients requiring additional procedures was maximum for combination of Gram-negative and fungus (66.7%) followed by Gram-positive and Gram-negative combination (42.1%) (Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}).

###### 

Comparison of secondary interventions and visual outcome among different microbes in polymicrobial endophthalmitis

                                               **Gram**-**positive and gram**-**negative combination**   **Gram**-**positive and gram**-**negative combination**   **Gram**-**positive and fungus combination**   **Gram negative and fungus combination**
  ------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------- ------------------------------------------
  No. of patients                                                        12                                                        19                                                   9                                            3
  Undergoing secondary intervention                                   2 (16.7%)                                                 8 (42.1%)                                           2 (22.2%)                                    2 (66.7%)
  Unfavorable visual outcome (VA \< 20/200)                            9 (75%)                                                 17 (89.5%)                                           6 (66.7%)                                    2 (66.7%)

Visual outcomes
---------------

An unfavorable visual outcome (VA \< 20/200) resulted in 27 out of 31 patients (87.1%) having posttraumatic endophthalmitis and four out of nine (44.4%) patients having postoperative endophthalmitis. Combination of Gram-positive and Gram-negative organisms had the worst visual prognosis with only 10.5% patients having final VA ≥ 20/200. Out of the 43 patients, only 9 (20.9%) patients had a best corrected VA ≥ 20/200 at final follow-up. Eight out of 12 patients (66.67%) having fungi as one of the infecting organisms had a VA \< 20/200 at final follow-up visit.

Discussion
==========

Polymicrobial eye infections present a challenge not only in identifying two or more microorganisms, but also in instituting appropriate antimicrobial therapy. In the current study and in large series, polymicrobial infections seem to occur more frequently in open-globe injuries, underscoring the non-sterile conditions under which ocular trauma occurs. Polymicrobial infections have been reported following advanced keratitis, infected scleral buckles, and dacryocystitis \[[@B13]-[@B15]\]. In a retrospective study from North India, Gupta et al. reported polymicrobial endophthalmitis in 8 eyes out of 47 culture-positive postoperative endophthalmitis eyes (17%) \[[@B11]\]. Pijl et al. from Netherlands found polymicrobial infection in 4 out of 166 culture-positive cases (2.4%) of postoperative endophthalmitis \[[@B12]\]. Anand et al., in a series of 170 culture-proven postoperative endophthalmitis, reported 3 cases (1.8%) of polymicrobial endophthalmitis \[[@B16]\]. Vedantham et al., reported 3 (7.7%) polymicrobial endophthalmitis cases in a series of 39 posttraumatic patients \[[@B17]\]. In the author\'s previous published report for the period 1991 to 1997, polymicrobial infections were identified in 12.5% (14 of 112) culture-positive postoperative cases, while it was present in 20.4% (23 of 113) culture-positive posttraumatic cases, with three trimicrobial cases \[[@B2],[@B9]\]. In the current series from 2000 to 2010, less prevalence of polymicrobial infection (3.88%) was observed compared with the earlier report. The cause for this decrease in prevalence of polymicrobial infection is uncertain.

Gram-positive bacteria (*S*. *epidermidis* and *S*. *pneumoniae*) are the most common isolates from polymicrobial endophthalmitis in the current series, contrasting with the previous series where Gram-negative bacteria and fungus were most common isolates.

Considering the very short half-life of fluoroquinolones but good penetration in vitreous cavity, this class of antibiotics can be considered for per-oral therapy, and vancomycin can be considered for intravitreal injections. Repeat intravitreal antibiotics if needed should be based on culture sensitivity report.

Patients with posttraumatic endophthalmitis had poorer visual outcomes when compared with postoperative endophthalmitis, which is consistent with our previous series and previous reported literature \[[@B2],[@B7]-[@B9]\]. Five out of nine postoperative patients (55.5%) having polymicrobial infection had favorable visual outcome as compared with only 4 patients out of 31 (12.9%) having posttraumatic endophthalmitis. The number of patients undergoing additional procedure was also more for posttraumatic cause (38.7%) as compared with postoperative cause (11.1%). We had three patients with endogenous source of infection who had polymicrobial infection, and all three had unfavorable visual outcome.

Although prevalence of fungus in our series has decreased, given the unsterile conditions under which traumatic endophthalmitis occurs and high probability of fungal contamination, intravitreal antifungal agents should be considered along with antibiotics, but decision should be individualized based on history and clinical examination. Limitations of the current study include the retrospective nature and lack of a definitive prospective treatment protocol.

Conclusions
===========

Polymicrobial infections in endophthalmitis are uncommon and are often associated with trauma. Coinfection with Gram-negative bacteria or fungi may be associated with the most unfavorable visual acuity outcomes.

Methods
=======

Approval was obtained from the local Institutional Review Board. All the patients who were diagnosed with endophthalmitis during the period 2000 to 2010 were analyzed. From the endophthalmitis database, information was obtained regarding the cause of endophthalmitis, microbiological work up including the vitreous isolates and their antibiotic susceptibilities, and the clinical outcomes. All patients with more than one isolate during microbiological workup were enrolled in the study.

The EVS recommendations were generally followed in postoperative endophthalmitis eyes. In endophthalmitis following open-globe injuries, three-port pars plana vitrectomy was performed in all eyes along with additional procedure if required (suturing scleral laceration, IOFB removal, endolaser, or silicone oil injection). Undiluted vitreous samples were sent immediately for microbiology evaluation. All eyes received intravitreal vancomycin (1.0 mg in 0.1 ml) and either amikacin (0.4 mg in 0.1 ml) or ceftazidime (2.25 mg in 0.1 ml) and additional intravitreal dexamethasone (0.4 mg in 0.1 ml) in postoperative cases. Intravitreal amphotericin B (5 μg in 0.1 ml) was administered on clinical suspicion based on surgeon's treatment preference. Additional procedures were recorded when intravitreal antimicrobials or pars plana vitrectomy/vitreous lavage were repeated. Treatment and management decisions on secondary interventions were made by the individual treating physician without a predefined study protocol. Bacterial isolates were identified using Analytical Profile Index (API, bioMeriux, Marcy-l\'Etoile, France). The antibiotic sensitivity was checked by Kirby Bauer disc diffusion method. Isolation of two or more different organisms from vitreous was considered to be a polymicrobial infection. The best-corrected visual acuity of less than 20/200 at final follow-up was defined as unfavorable visual outcome.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

AJ carried out the data analysis and drafted the manuscript. MRM and MK carried out the data collection. AP is one of the treating physician and also carried out the correction of the manuscript. SJ, AM, AM, TD are the other treating physicians. SS is the microbiologist. HWFJ corrected the manuscript. All authors read and approved the final manuscript.
